Company Overview
Thrombotech Ltd. is an Israeli biotechnology company established around years of cutting-edge thrombotic research at the
Hadassah Medical Center in Jerusalem.
Thrombotech developed a peptide, THR-18, which allows the existing thrombolytic stroke medication to easily dissolve blood clots,
diminishing its life-threatening side effects and improving its efficacy.
THR-18 significantly expands the use of the current stroke treatment, tissue Plasminogen Activator, or tPA, by improving its thrombolytic
properties and by eliminating the risk of intra-cerebral hemorrhages and other life-threatening side effects that are restricting the use of
tPA to only approximately 5-10% of embolic stroke patients.
Despite its brief therapeutic window and risk of brain hemorrhages, tPA remains the only FDA-approved treatment for acute stroke,
leaving the vast majority of embolic stroke patients with limited medical treatment. By eliminating tPA’s negative side effects and
addressing needs that tPA currently leaves unmet, THR-18 has the power to save millions of lives and cut medical costs tremendously. |
